The American Heart Association and American College of Cardiology Foundation have issued new guidelines for secondary prevention and risk reduction in patients with atherosclerotic vascular disease.
The American Heart Association (AHA) and American College of Cardiology (ACC) Foundation have issued new guidelines for secondary prevention and risk reduction in patients with atherosclerotic vascular disease. The new guidelines are available in Circulation and the Journal of the American College of Cardiology.
They update 2006 guidelines on secondary prevention and add risk-factor reduction “because important evidence from clinical trials has emerged that further supports and broadens the merits of intensive risk-reduction therapies for patients with established coronary and other atherosclerotic vascular disease (including peripheral artery disease),” according to the writing committee.
The guideline’s foundation continues to be patient behavior, including physical exercise, smoking cessation, and avoidance of second-hand smoke, and weight management. The guidelines recommend patients participate in at least 30 minutes of physical activity every day.
“Unless improvements are made in behavior and medical therapy, the same blood vessel problem that caused [the] first heart attack or stroke can occur again – and may result in death – so long-term changes need to be initiated to get the vascular disease under control,” said Sidney C. Smith Jr, MD, chair of the guideline writing group and professor of medicine at the University of North Carolina.
The guidelines include a new recommendation emphasizing the importance of referring patients for cardiac rehabilitation, and they include sections on other often-overlooked factors that can influence patients’ outcomes, such as depression and flu shots.
AHA and ACC Foundation released the guidelines even though they are waiting for the new Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 8) guidelines and new Adult Treatment Panel 4 (ATP 4) guidance on lipid management. The National Heart, Lung, and Blood Institute projects those guidelines won’t be available until 2012.
CVS Caremark Makes Changes in Diabetes Coverage for 2025
November 25th 2024CVS Caremark has removed several therapies to treat patients with diabetes in favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More